EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine

Leukemia

Volumn 26, Issue 9, 2012, Pages 1899-1907

  Van Dongen, J J M ^a   Orfao, A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; FLUOROCHROME; HYBRID PROTEIN;

ACUTE LEUKEMIA; ANTIBODY CLONE; CANCER DIAGNOSIS; CANCER SCREENING; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLONE; CONJUGATION; DIAGNOSTIC ACCURACY; EPITOPE MAPPING; EUROFLOW; FLOW CYTOMETRY; IMMUNOPHENOTYPING; LABORATORY DIAGNOSIS; LEUKEMIA; LYMPHOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SCIENTIST; STANDARDIZATION;

HUMANS; IMMUNOPHENOTYPING; INDIVIDUALIZED MEDICINE; LEUKEMIA; LYMPHOMA;

EID: 84865838761     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.121     Document Type: Review

References (43)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. International Agency for Research on Cancer: Lyon, 2008, 439 pp.
2. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-417. (Pubitemid 33585945)
3. Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem 1999; 45: 1708-1717. (Pubitemid 29477326)
4. Szczepanski T, van der Velden VH, van Dongen JJ. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clin Chem Lab Med 2006; 44: 775-796.
5. Davis BH, Holden JT, Bene MC, Borowitz MJ, Braylan RC, Cornfield D et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom 2007; 72(Suppl 1): S5-S13. (Pubitemid 350194343)
6. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3941-3967.
7. Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom 2008; Chapter 6 Unit 6.25.
8. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010; 78: 239-252.
9. Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011; 25: 567-574.
10. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993; 100: 534-540. (Pubitemid 23346202)
11. Knapp W, Strobl H, Majdic O. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry 1994; 18: 187-198.
12. Groeneveld K, te Marvelde JG, van den Beemd MW, Hooijkaas H, van Dongen JJ. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Leukemia 1996; 10: 1383-1389. (Pubitemid 26261440)
13. Porwit-MacDonald A, Bjorklund E, Lucio P, van Lochem EG, Mazur J, Parreira A et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7 + cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000; 14: 816-825. (Pubitemid 30235058)
14. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: International Standardization and Clinical Evaluation. Leukemia 2001; 15: 1185-1192.
15. Lanza F. Towards standardization in immunophenotyping hematological malignancies. How can we improve the reproducibility and comparability of flow cytometric results? Working Group on Leukemia Immunophenotyping. Eur J Histochem 1996; 40(Suppl 1): 7-14. (Pubitemid 126635636)
16. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia 1996; 10: 877-895. (Pubitemid 26168408)
17. Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007; 72(Suppl 1): S14-S22. (Pubitemid 350194344)
18. Greig B, Oldaker T, Warzynski M, Wood B. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: recommendations for training and education to perform clinical flow cytometry. Cytometry B Clin Cytom 2007; 72(Suppl 1): S23-S33. (Pubitemid 350194345)
19. van Dongen JJM, Orfao A, Staal FJT, Martin-Ayuso M, Parreira A, Kneba M et al. EuroFlow: Flow cytometry for fast and sensitive diagnosis and follow-up of haematological malignancies. In: European Commission. Genomics and Biotechnology for Health-Diagnostics. Office for Offical Publications of the European Communities: Luxembourg, 2008, pp 54-56.
20. van Dongen JJM, Lhermitte L, Bö ttcher S, Almeida J, van der Velden VHJ, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.
21. Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, Bö ttcher S, Ritgen M et al. EuroFlow standardization of flow cytometry instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986-2010.
22. Pedreira CE, Costa ES, Barrena S, Lecrevisse Q, Almeida J, van Dongen JJ et al. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A 2008; 73: 834-846.
23. Costa ES, Pedreira CE, Barrena S, Lecrevisse Q, Flores J, Quijano S et al. Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia 2010; 24: 1927-1933.
24. Weerkamp F, Dekking E, Ng YY, van der Velden VH, Wai H, Bottcher S et al. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 2009; 23: 1106-1117.
25. Dekking E, van der Velden VH, Bottcher S, Bruggemann M, Sonneveld E, Koning-Goedheer A et al. Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Pract Res Clin Haematol 2010; 23: 333-345.
26. Dekking EHA, van der Velden VHJ, Varro R, Wai H, Bö ttcher S, Kneba M et al. Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia. Leukemia 2012; 26: 1976-1985.
27. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956-964. (Pubitemid 46672072)
28. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438. (Pubitemid 351398645)
29. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
30. Stewart CC, Behm FG, Carey JL, Cornbleet J, Duque RE, Hudnall SD et al. U.S. Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations. Cytometry 1997; 30: 231-235.
31. Ruiz-Arguelles A, Duque RE, Orfao A. Report on the first Latin American Consensus Conference for Flow Cytometric Immunophenotyping of Leukemia. Cytometry 1998; 34: 39-42.
32. Basso G, Buldini B, De Zen L, Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001; 86: 675-692. (Pubitemid 32680993)
33. Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry B Clin Cytom 2006; 70: 39-44. (Pubitemid 43075997)
34. Stetler-Stevenson M, Ahmad E, Barnett D, Braylan R, DiGiuseppe J, Marti G et al. Clinical flow cytometric analysis of neoplastic hematolymphoid cells; Approved guideline. 2nd edn. CLSI document H43-A2 ed. Clinical and Laboratory Standards Institute: Wayne, PA, 2007.
35. Beckman Coulter Inc. Beckman Coulter Flow Cytometers. Clinical Flow Cytometry Instruments. Available from http://www.beckmancoulter.com/wsrportal/ wsr/diagnostics/clinical-products/flow-cytometry/flow-cytometers/index.htm (cited 2 September 2011).
36. Wilson WH. International consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia. Cytometry B Clin Cytom 2007; 72(Suppl 1): S2. (Pubitemid 350194341)
37. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94: 1124-1134.
38. Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry 2001; 46: 98-104. (Pubitemid 32423460)
39. Aguilar H, Alvarez-Errico D, Garcia-Montero AC, Orfao A, Sayos J, Lopez-Botet M. Molecular characterization of a novel immune receptor restricted to the monocytic lineage. J Immunol 2004; 173: 6703-6711. (Pubitemid 39541055)
40. Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res 2009; 33: 1212-1216.
41. van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. Leukocyteassociated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur J Immunol 1999; 29: 3160-3167. (Pubitemid 29484206)
42. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40: 259-263.
43. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-1645. (Pubitemid 24323778)